<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734640</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMISTmain</org_study_id>
    <nct_id>NCT03734640</nct_id>
  </id_info>
  <brief_title>Optimal Post Tpa-Iv Monitoring in Ischemic Stroke</brief_title>
  <official_title>Optimal Post Tpa-Iv Monitoring in Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig Anderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The George Institute for Global Health, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute for Global Health, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OPTIMISTmain is an investigator-initiated and conducted, international, multicentre, stepped&#xD;
      wedge cluster randomized controlled trial comparing the effects of different intensities of&#xD;
      nursing care monitoring for patients with acute ischemic stroke of mild severity and without&#xD;
      critical care needs after IV-tPA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research question: Patients receiving thrombolytic therapy (tissue plasminogen activator&#xD;
      [tPA]) for acute ischaemic stroke (AIS), have been monitored with a high intensity schedule&#xD;
      of vital signs and neurologic assessments, which often requires 1:1 nursing and/or admission&#xD;
      in an intensive care unit (ICU) or similar ward for at least 24 hours after receiving tPA.&#xD;
      Studies indicate that patients with mild degrees of AIS after tPA do not require such&#xD;
      intensive monitoring, yet most stroke services continue to follow a practice recommended in&#xD;
      guidelines based on the initial cautious evaluation of tPA in AIS over 20 years ago.&#xD;
&#xD;
      Design: Stepped-wedge cluster randomised design. With 3 groups and 4 phases. All groups&#xD;
      starting with standard care and in each subsequent phase, groups I through III will switch to&#xD;
      the intervention (low-intensity monitoring).&#xD;
&#xD;
      Study centers: This is a global study. Approximately 157 hospitals ('sites') in Australasia,&#xD;
      Europe, South American, and North American regions, who are willing to accept the randomized&#xD;
      intervention change and adhere to the protocol, collect a required minimum data set on&#xD;
      patients over 7 days in hospital (or discharge or death, if sooner), and record any serious&#xD;
      adverse event (SAE) during and at clinical outcome assessed at 90 days of follow-up of&#xD;
      patients.&#xD;
&#xD;
      Consent/randomization: Hospitals will be eligible if they are using the proposed&#xD;
      low-intensity nursing monitoring strategy. A stepped-wedge cluster randomized design has been&#xD;
      chosen to avoid contamination, facilitate hospital-wide implementation, and maximize&#xD;
      adherence, as the intervention under investigation is to become usual standard of care. The&#xD;
      process of one direction (from control to intervention) is to facilitate the low intensity&#xD;
      monitoring protocol being applied in clinical practice. The stepped-wedge design means that&#xD;
      all hospitals will be randomly allocated to 3 groups: in phase 1, all hospitals will be&#xD;
      observed under standard care 'control' conditions according to guideline recommended&#xD;
      monitoring; in phase 2, the first cluster of hospitals (Group I) will start receiving the&#xD;
      intervention (low-intensity), and then sequentially, Groups II and III will start receiving&#xD;
      the interventional package in phase 3 and 4, respectively, so that by phase 4, all hospitals&#xD;
      will have the intervention. Those hospitals in Group I are exposed to the intervention for&#xD;
      longest time, and those in Group III, the shortest time.&#xD;
&#xD;
      In each phase, hospitals are to maintain a register of all thrombolyzed AIS patients, and to&#xD;
      identify all those eligible for, or excluded from participating in the study. Hospitals are&#xD;
      required to manage at minimum target of at least 10 consecutive thrombolyzed AIS patients who&#xD;
      fulfill the eligibility criteria (presumed 50% of all thrombolyzed AIS patients) over each 4&#xD;
      month period. The recruitment number will vary from 10 to 30 patients, according to seasonal&#xD;
      fluctuation and overall numbers of thrombolyzed AIS patients across hospitals. The target&#xD;
      number and time limits for each phase will be pre-determined and agreed to with each&#xD;
      hospital, to ensure an orderly completion of the study.&#xD;
&#xD;
      On average, for Group I, the time for initiation of the low-intensive intervention is 4&#xD;
      months after activation into phase 1 of the study; for Groups II and III, the time periods&#xD;
      for initiation of the low-intensive intervention are 6 and 9 months, after activation,&#xD;
      respectively. Data collection will occur at baseline, the first 24 hours, Day 7 (or death or&#xD;
      time of hospital discharge, if earlier), and at 90 days (end of follow-up). Patients will be&#xD;
      asked to consent to being contacted at some future date to examine long-term outcomes,&#xD;
      according to available resources.&#xD;
&#xD;
      A senior executive officer at each center will act as a 'guardian', to provide consent at an&#xD;
      institutional level for the intervention to be applied as a 'low risk' intervention to&#xD;
      clusters of patients as part of routine care; and written informed consent is to be&#xD;
      subsequently obtained from participants, or their approved surrogates, for collection of&#xD;
      medical data and participation in the follow-up assessments Randomized allocation of&#xD;
      intervention will be assigned by a statistician not otherwise involved in the study according&#xD;
      to a statistical program stratified by the country of the site.&#xD;
&#xD;
      Sample size: The sample size required to detect a plausible treatment effect on a clinical&#xD;
      outcome in a stepped-wedge trial (3 groups, 4 phases) is 157 hospitals, each recruiting an&#xD;
      average of 80 patients (20 per phase), for a total of 12,394 AIS patients. The basis of this&#xD;
      calculation is that the study is designed with 90% power (one-sided Î± = 0.025) to detect&#xD;
      non-inferiority (non-inferiority OR margin is 1.25, presumed actual OR is 1.0; the proportion&#xD;
      of a bad outcome [mRS 2-6] is 50%) of low-intensity monitoring on the primary outcome.&#xD;
      Assuming a stepped-wedge trial of 3 groups and 4 phases, 157 hospitals are required to be&#xD;
      randomized into 3 groups of 53 hospitals, each recruiting an average of 16 patients per&#xD;
      phase, for a total of 9340 subjects. Assuming 10% with missing primary endpoint data and 5%&#xD;
      with nonadherence to randomized treatment, the overall sample size increases to an average of&#xD;
      20 subjects per hospital per phase (i.e. total sample size of 12,394 AIS patients). Allowance&#xD;
      will be made to include some very large hospitals (10%, 7) to recruit 50 patients per phase,&#xD;
      and smaller hospitals (10%, 7) to recruit 8 patients per phase, in order to allow a broad&#xD;
      range of hospitals with variable experience and systems of care for the management of AIS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>stepped wedge cluster randomized</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Guardian consent for intervention as standard of care service provision. Outcome assessed by independent researcher blind to treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin scale (mRS); shift analysis across full range of scores</measure>
    <time_frame>day 90</time_frame>
    <description>Physical function measured according to a 7 level categorical scale, where 0-1 indicates no or minimal symptoms, 2-5 indicates increasing levels of disability/dependencey, and 6=death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of major Symptomatic intracerebral hemorrhage</measure>
    <time_frame>day 90</time_frame>
    <description>intracerebral hemorrhage on brain imaging associated with significant neurological deterioration or death over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of hospital costs</measure>
    <time_frame>day 90</time_frame>
    <description>to allow economic analysis of treatment interventions at a country level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any serious adverse event during follow-up</measure>
    <time_frame>Within 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7200</enrollment>
  <condition>Acute Ischemic Stroke Patients Receiving Reperfusion Therapy</condition>
  <arm_group>
    <arm_group_label>Guideline recommended standard monitoring</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-intensity monitoring strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-intensity monitoring strategy</intervention_name>
    <description>Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment</description>
    <arm_group_label>Low-intensity monitoring strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Guideline recommended standard monitoring</intervention_name>
    <description>Post-tpa patients will be monitored in the usual care monitoring environment</description>
    <arm_group_label>Guideline recommended standard monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults (age â¥18 years);&#xD;
&#xD;
          -  have received IV alteplase for AIS according to standard criteria;&#xD;
&#xD;
          -  have a mild-moderate level of neurological impairment (e.g. score &lt;10 on the NIHSS);&#xD;
&#xD;
          -  stable and without any critical care needs at the end of the infusion of alteplase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  major neurological impairment;&#xD;
&#xD;
          -  definite clinical contraindication or indication to either low-intensity or standard&#xD;
             neurological monitoring.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig S Anderson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor C Urrutia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Anderson, PhD</last_name>
    <phone>+61 410476311</phone>
    <email>canderson@georgeinstitute.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor C Urrutia, MD</last_name>
    <phone>+1 410-955-2228</phone>
    <email>vurruti1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centura St. Anthony Hospital</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Aguilar</last_name>
      <email>mariaaguilar@centura.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centura Littleton Adventist Hospital</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaela Alexander</last_name>
      <email>alexandermd@coneurodiagnostics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Yarbrough</last_name>
      <email>kyarbrough@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Urrutia</last_name>
      <email>vurruti1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard County General Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Aldrich</last_name>
      <email>ealdrich@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Silver</last_name>
      <email>Brian.Silver@umassmemorial.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Cohen</last_name>
      <email>lcohen1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Silverman</last_name>
      <email>bruce.silverman@ascension.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SSM Health DePaul Hospital</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amer Alshekhlee</last_name>
      <email>Amer.Alshekhlee@ssmhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Olds</last_name>
      <email>kolds@saint-lukes.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifthekar Ahmed</last_name>
      <email>ifthekar.Ahmed@hcahealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renown Health</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burton Tabaac</last_name>
      <email>Burton.Tabaac@renown.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Leonhardt-Caprio</last_name>
      <email>Ann_Leonhardt@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cone Health</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sethi Pramod</last_name>
      <email>Pramod.Sethi@conehealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute - Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Rai</last_name>
      <email>vivek.rai@ohiohealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INTEGRIS Southwest Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Barghols</last_name>
      <email>john.barghols@integrisok.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claranne Mathiesen</last_name>
      <email>claranne.mathiesen@lvhn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Health</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Reichwein</last_name>
      <email>rreichwein@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laith Altaweel</last_name>
      <email>laith.altaweel@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheila Jala</last_name>
      <email>Sheila.Jala@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Puerto Montt</name>
      <address>
        <city>Puerto Montt</city>
        <state>Los Lagos</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Rivero</last_name>
      <email>mariosurcouf@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Alemana de Santiago</name>
      <address>
        <city>Santiago</city>
        <state>RegiÃ³n Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Mazzon</last_name>
      <email>emazzon@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Pino</name>
      <address>
        <city>Santiago</city>
        <state>RegiÃ³n Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego Rocha</last_name>
      <email>drochaj@udd.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Padre Hurtado</name>
      <address>
        <city>Santiago</city>
        <state>RegiÃ³n Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Almeida</last_name>
      <email>jalmeida@alemana.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital SÃ³tero del Rio</name>
      <address>
        <city>Santiago</city>
        <state>RegiÃ³n Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andres Silva</last_name>
      <email>andressilvap@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The George Institute for Global Health, China</investigator_affiliation>
    <investigator_full_name>Craig Anderson</investigator_full_name>
    <investigator_title>Executive Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>12 months after completion of the study, experienced researchers can seek a copy of the database through requests to the Research Office of The George Institute</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>12 months after primary results publication</ipd_time_frame>
    <ipd_access_criteria>Request with protocol to the Research Office of The George Institute</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

